SSA
GYRE icon

Schonfeld Strategic Advisors’s Gyre Therapeutics GYRE Stock Holding History

Schonfeld Strategic Advisors’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-11,920
Closed -$367K – 2304
2021
Q3 		$367K Sell
11,920
-720
-6% -$23.7K ﹤0.01% 1425
2021
Q2 		$411K Buy
12,640
+1,253
+11% +$43K ﹤0.01% 1290
2021
Q1 		$431K Buy
+11,387
New +$520K 0.01% 1196
2020
Q4 		– Sell
-1,800
Closed -$58K – 1686
2020
Q3 		$58K Sell
1,800
-9,819
-85% -$384K ﹤0.01% 1301
2020
Q2 		$511K Buy
+11,619
New +$546K 0.01% 797
2018
Q3 		– Sell
-6,733
Closed -$589K – 889
2018
Q2 		$589K Buy
6,733
+3,150
+88% +$553K 0.03% 504
2018
Q1 		$693K Buy
+3,583
New +$668K 0.05% 404

Other funds holding GYRE

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Schonfeld Strategic Advisors's GYRE Position: Q4 2021 in Review

Schonfeld Strategic Advisors sold out of Gyre Therapeutics (GYRE) in Q4 2021, closing a stake of 11,920 shares — an estimated $367K sold.

Schonfeld Strategic Advisors first reported a position in GYRE in Q1 2018 and held it in 7 quarters. The position peaked at $693K in Q1 2018. 51 funds tracked by Wall St. Rank hold GYRE as of Q4 2021.

  • Schonfeld Strategic Advisors reported no remaining Gyre Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 11,920 Gyre Therapeutics shares in Q4 2021, an estimated $367K.
  • Schonfeld Strategic Advisors first reported a position in Gyre Therapeutics in Q1 2018 and held it in 7 quarters.
  • Schonfeld Strategic Advisors's Gyre Therapeutics position peaked at $693K in Q1 2018.
  • 51 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q4 2021.

Based on Schonfeld Strategic Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.